Company intelligence / Profile preview

iCAR Bio Therapeutics

Zhongshan, Guangdong, China

Ownership: Private
Development stage: Other

Overview

iCAR Bio Therapeutics is developing next-generation CAR-T cell therapies targeting hematological malignancies, leveraging a platform for dual-antigen targeting and novel surface antigens. No clinical efficacy data publicly available as of June 2025; most programs are preclinical/early translational

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Drug pipeline

1 asset

ICG181

Preclinical

Beyond the preview

Go deeper on iCAR Bio Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iCAR Bio Therapeutics.

Explore the full profile